malaria_record: 94

Data license: Public Domain (CDC) · Data source: CDC Travelers' Health (Yellow Fever & Malaria, by country)

This data as json

record_id country_id valid_from valid_to is_current source_id fetch_run_id payload_sha256 content_hash area_of_risk_html relative_risk_html chloroquine_resist_html species_html recommended_prophylaxis_html cdc_updated_date has_transmission is_endemic whole_country_endemic country_has_any_prophylaxis_area screening_class prophylaxis_drugs_json species_json chloroquine_resistant area_summary created_at
94 94 2026-06-03   1 1 1 8eab5796788447f748d742bc3ea9c689b7dd02e0761828d2fa9fd151f54f3515 8fdd091c8d048245f960da4ed65067c38025fab68fa076f839cb80fd53bc87bd
  • Areas <1,500 m (<5,000 ft) elevation in the provinces of Cotopaxi, Esmeraldas, Morona-Santiago, Orellana, Pastaza, and Sucumbíos
  • Rare cases <1,500 m (<5,000 ft) in all other provinces
  • No malaria transmission in the cities of Guayaquil or Quito (the capital)
  • No malaria transmission on the Galápagos Islands
  
  • Chloroquine
  • P. vivax (85%)
  • P. falciparum (15%)
  • Transmission areas in the provinces of Cotopaxi, Esmeraldas, Morona-Santiago, Orellana, Pastaza, and Sucumbíos: Atovaquone-proguanil, doxycycline, mefloquine, tafenoquine2
  • All other areas with reported malaria transmission: No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only)4
Updated April 23, 2025
 2025-04-23 1 1 0 1 partial ["atovaquone-proguanil", "doxycycline", "mefloquine", "tafenoquine"] ["P. falciparum", "P. vivax"] 1 2 risk area statement(s); 2 no-transmission exclusion(s) 2026-06-03T22:10:28Z

Links from other tables